A comparative study of the treatment outcomes in Alcoholic Liver Disease patients treated with Ursodeoxycholic acid and Methionine along with Abstinence (Placebo) by jagarlamudi, anup et al.
Jagarlamudi et al                                                                                                 Journal of Drug Delivery & Therapeutics. 2019; 9(3):292-299 
ISSN: 2250-1177                                                                                  [292]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.05.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
A comparative study of the treatment outcomes in Alcoholic Liver Disease 
patients treated with Ursodeoxycholic acid and Methionine along with 
Abstinence (Placebo) 
Dr.Anup Jagarlamudi 1, M.S.V.V.N Prasanna Kamakshi 2, Shayeesta Tabassum 2, N.Nikitha Reddy 2, K.Hemanthkumar 2 
1 Associate Professor, Department of Pharmacy Practice, KVK college Of Pharmacy, Hyderabad, Telengana State, India. 501512.  
2 Fifth year Pharm.D., KVK college of Pharmacy, Hyderabad, Telengana state, India. 501512. 
 
ABSTRACT 
Liver is extremely active organ in the body. Ethanol toxicity on liver is a function of duration of alcoholism, amount of daily intake of alcohol and 
patient's nutrition. Ethanol is oxidized in the liver to acetaldehyde--a compound considerably more toxic than ethanol itself. Despite small 
amount of alcohol dehydrogenase (ADH) found in gastric mucosa, the metabolism of ethanol in this site may have an important 
hepatoprotective effect. ATP synthesis rate is reduced in the liver cells when exposed to ethanol... ethanol is metabolised by two ways 
1.Conversion of ethanol to acetaldehyde by Alcoholdehydrogenase. 2. Conversion of acetaldehyde to acetate by Acetaldeydrogenase.  Chronic 
ethanol consumption does not influence ADH activity, but has a profound stimulatory effect on microsomal enzymes, in particular cytochrome 
CYP2E1. Alcohol increases the flow of blood in the portal and hepatic vascular resistance results increased portal pressure and collateral blood 
flow which causes the visceral bleeding in patients with alcoholic cirrhosis and portal hypertension. The aim of the study is to evaluate the 
outcome of ursodeoxycholic acid (300mg),methionine (400mg)and abstinence in the treatment of alcoholic liver disease and the objective is to 
achieve the following end points(primary end point -change from baseline in particular LFT parameter-albumin and CBP parameters such as PT 
and INR ratio)(secondary end point- effects of ursodeoxycholic acid and methionine on other LFT parameters such as total bilirubin, SGOT, 
SGPT along with changes in the  above parameters in patients with abstinence.)The significance is though ursodeoxycholic acid and methionine 
drugs have well known effect on the  liver function test parameters of SGOT and SGPT and total bilirubin, here we are assessing the effects of 
these two drugs in particular LFT parameter i.e albumin and CBP parameters i.e prothrombin and INR that may help us to know more about the 
drug’s efficacy . In particular Liver function test parameters meant for the study are Bilirubin, SGOT, SGPT, Albumin. By assessing the particular 
parameters of the study, we concluded the following outcomes: At the end of the study, group 1 has shown 60% improvement, Gro up 2 has 
shown 50 % improvement from baseline to the end of the study. Group 3 has not shown much improvement when compared to the study 
medications i.e there is an overall improvement of only 30 % from baseline. By the end of the study scruitinizing all the laboratory parameters 
it is   observed that of the three groups, group 1 and group 2 has better treatment outcomes than group 3 and hence it is concluded that medical 
intervention is more effective over complete abstinence and concluded that early medical intervention is a better option for better outcomes.  
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INTRODUCTION 
Liver is extremely active organ in the body. It is the largest 
gland weighing between 3.17 and 3.66 pounds (lb), or 
between 1.44 and 1.66 kilograms (kg), the liver is reddish-
brown with a rubbery texture. 
The liver is classed as a gland and associated with many 
functions. It is difficult to give a number, as the organ is still 
being explored, but it is thought that the liver carries out 500 
distinct roles. [1] 
Liver disease can be defined as any disturbance of liver 
function that causes illness. The liver is responsible for many 
critical functions within the body. The loss of those functions 
can cause significant damage to the body. Liver disease is 
also referred to as a hepatic disease. Liver disease is a broad 
term that covers the potential problems which causes the 
liver to fail to perform its designated functions. Usually, 
more than 75% or three quarter of liver tissue needs to be 
affected before decrease in function occurs.[2] 
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Disease Spectrum: 
Alcoholic fatty liver:  
It is invariable if consumption exceeds 80g of alcohol per 
day. Effected hepatocytes occupied by the triglyceride 
accumulation but there is a normal liver function. It is 
reversible on abstinence.[3] 
Alcoholic hepatitis:  
Hepatocyte ballooning occurs due to increased intracellular 
water accumulation.  Mallorys hyaline bodies are 
perinuclear eosinophilic inclusion bodies and are probably 
condensed and disorganized fragments of the cytoskeleton 
framework of the hepatocyte. These bodies are the 
characteristic of this condition. 15-20 years of excessive 
drinking estimated to develop alcohol hepatitis.[3] 
Liver cirrhosis: 
Liver cirrhosis is a irreversible damage of liver. It is a 
progressive parenchymal necrosis, regeneration and diffuses 
fibrosis, leading to disorganization of architecture of lobular 
throughout the whole liver. These nodules or lobules are 
called as pseudo lobules. This may be termed as 
micronodules or macronodules depending upon their size. 
Localized deficit such as nodular hyperplasia do not 
constitute cirrhosis because histological abnormality should 
involve the entire liver.[3] 
Alcohol is a leading cause of liver disease. It is consumed in 
most regions of the world; two billion people worldwide 
consume alcoholic beverages. It is estimated that 76.3 
million   have a diagnosable alcohol use disorders by World 
Health Organization.  It is responsible for over 2.5 million 
deaths every year and alcoholic liver disease (ALD) accounts 
for a large portion of alcohol related morbidity and 
mortality. Alcoholic liver disease is a spectrum of clinical 
illness and morphological changes that range from fatty liver 
to hepatic inflammation and necrosis (alcoholic hepatitis) to 
progressive fibrosis (alcoholic cirrhosis).Alcohol is the world 
third largest risk factor for disease burden. Consumption of 
alcohol results in 2.5 million deaths each year. 
Liver cirrhosis mortality in the world is 23.54% and it ranks 
27th as a cause of death in the world majorly.  
The World Health Organization (WHO) estimates that 140 
million people worldwide suffer from alcohol dependency, 
causing damage to lives and economies. In India, 15 people 
die every day – or one every 96 minutes – from the effects of 
drinking alcohol, reveals by an India Spend analysis of 2013 
National Crime Records Bureau (NCRB) data. Global status 
report on alcohol and health 2014 was released by WHO for 
India, Around 30% of total adult population consumes 
alcohol. 93% of alcohol consumes in the form of spirit. 7% in 
the form of beer and ≤1% in the form of wine. Highest 
alcohol consumption were found in Kerala (8 ltrs per 
annum) followed by   Maharasthra and Punjab. 11% adult 
population in India indulged in heavy drinking or binge 
drinking.[4] 
ATP synthesis rate is reduced in the liver cells when exposed 
to ethanol. Chronic alcohol consumption results in 
depressed activity of almost all mitochondrial complexes 
.This include decrease activity of cytochrome oxidase. 
Impaired proton translocation and electron transport, ATP 
synthesis complex is reduced and decreased cytochrome b 
content as a result energy metabolism is severely impaired 
and result in hepatic damage.[5] 
Hypoxia also alteres the energy metabolism.The liver cells 
increases the oxygen uptake by chronic ethanol 
administration because of the need of its metabolism, which 
occurs in the centilobular area of the liver lobule which lead 
to the increased blood flow to the liver. But increasing blood 
flow do not match the requirements derived from 
metabolism of ethanol. Thus, the responsible for liver injury 
is centri lobular hypoxia.Hypoxia and high ethanol blood 
levels might ensure from the combination of increased 
oxygen demand and reduced perfusion .When the ethanol 
levels in the blood decline, it restore the lobular perfusion 
and injury.[5] 
Oxidative stress:  
Ethanol is metabolized by two steps: 
 1. Conversion of ethanol to acetaldehyde by Alcohol 
dehydrogenase. 
 2. Conversion of acetaldehyde to acetate by Acetal 
deydrogenase . 
Acetaldehyde is toxic byproduct that damages the liver cells. 
Liver oxidative stress is increased through alcohol by 
generation of Reactive oxygen species (ROS) .In alcohol 
metabolism involves an excessive reduction  of nicotinamide 
adenine dinucleotide (NAD) which causes the impairment in 
gluconeogenesis and metabolism to ketogenesis and fatty 
acid synthesis. Under normal circumstances reduction of 
NAD to NADH is regulated by cell kreb’s cycle.[5] 
Excessive alcohol consumption causes the shift and causing 
impairment of gluconeogenesis and diversion of metabolism 
to ketogenesis and fatty acid synthesis, NADH assume a 
reduced state of electron transport chain components in 
mitochondria. This results transfer of electrons to the 
molecular oxygen to generate the reactive oxygen species 
(ROS) as superoxide anion leading to the cell damage. NADH 
inhibition of β-oxidation leads to the accumulation of 
intracellular lipids, thus promoting steatosis. Excessive 
alcohol consumption leads to the induction of CYP2E1 which 
is the pathway of alcohol metabolism. The interaction of 
CYP2E1 with cytochrome reductase lead to the production of 
superoxide radicles, which results in leaks of electrons in the 
respiratory chain and ROS production. ROS produce in this 
cascade can react with iron and generates even more potent 
hydroxyl, ferryl, and perferryl radicles which perpetuate the 
liver damage.[5] 
Immunological mechanism 
By product of acetaldehyde by ethanol metabolism 
covalently bind to proteins and form adducts, antigenic 
which stimulate the immunological mechanisms which lead 
to the tissue injury.  The expression of tumor necrosis factor 
–α (TNF –α), Interleukin (IL) –Iβ increased in alcoholic liver 
disease. while  IL-6 and anti inflammatory cytokines 
decreased . These cytokines produce collagen leading to liver 
fibrosis by stimulating stellate cells and other way variety of 
substance like bacterial endotoxins such as 
lipopolysaccharides increase the intestinal permeability on 
intake of alcohol. At last it would characterized by necro-
inflammation, apoptosis and fibrosis lead to liver disease i.e 
cirrhosis.[5] 
Alcohol increases the flow of blood in the portal and hepatic 
vascular resistance results increased portal pressure and 
collateral blood flow which causes the visceral bleeding in 
patients with alcoholic cirrhosis and portal hypertension.[3] 
Complications: 
Chronic liver disease and exposure to hepatotoxic 
substances causes damage to normal liver tissue resulting in 
an inflammatory response and abnormal collagen secretion. 
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The initial result of this inflammation and collagen secretion 
is hepatic fibrosis. Fibrosis, defined as the excessive 
accumulation of proteins, such as collagen, in the liver’s 
extracellular matrix, is currently considered a wound-
healing response to chronic liver injury. If fibrotic liver 
disease advances, collagen bands progress to bridging 
fibrosis and eventually frank hepatic cirrhosis.[6] 
 
 
Figure -1: Pathophysiology of alcoholic liver disease 
Ascites: 
Ascites is a Greek word meaning water bag or wineskin. 
Ascites is the lymphatic fluid accumulation in the peritoneal 
cavity. It is the clinical presentation of cirrhosis. Formation 
of ascites is due to the splanchnic artial hypertension and 
decreased peripheral resistance due to severe portal 
hypertension and hepatic insufficiency. This results systemic 
hypotension which causes increased activity of sympathetic 
nervous system and renin-angiotensin–aldosterone 
system,that causes increased sodium and water retention 
and production of vasoconstrictor. This fluid accumulates in 
the abdominal cavity leading to the formation of ascites.[6] 
Portal hypertension: 
The classical symptom of portal hypertension is 
development of varices. Varices is the abnormal blood flow 
from the portal to systemic circulation, bypassing the liver. 
Varices causes portal venous system decompression and 
lead to return of blood to the systemic circulation. At any 
level of gastrointestinal tract varices occurs but the clinical 
significance route is through the left gastric vein 
development of esophageal varices. In cirrhotic patients 
there is a visceral bleeding when pressure in portal venous 
is more than 12mmhg which is greater than vena cava 
pressure. 25% to 40% of cirrhotic patients cause 
haemorrhage and 25% to 30% are risk of death in each 
episode of  bleeding.Varices can be treated by decreasing the 
portal hypertension by pharmacological and surgical 
approaches.[6] 
Hepatic encephalopathy: 
Hepatic encephalopathy occurs with significant liver 
dysfunction with a reversible neuropsychiatric complication 
namely portosystemic shunting, metabolic dysfunction and 
alteration of blood brain barrier. Neurotoxic and neuroactive 
substance such as ammonia pass through the liver which is 
in disease condition and bypass the shunts then go directly 
to brain. Other substances like γ-amino butyric acid (GABA) 
and Glutamate are implicated in causing the hepatic 
encephalopathy. Trival lack of awareness, altered mental 
state to asterixis are the clinical feature of hepatic 
encephalopathy, even go to gross disorientation and coma. 
Symptoms like impaired judgment, altered personality, 
euphoria or anxiety occur in the lowgrade encephalopathy.[7] 
Albumin:  
Serum albumin often referred to simply as blood albumin is 
an albumin ( a type of globular protein ) found in vertebrate 
blood .  
Serum albumin is produced by the liver, occurs dissolved in 
blood plasma in mammals. Albumin is essential for 
maintaining the oncotic pressure needed for proper 
distribution of body fluids between blood vessels and body 
tissues, without albumin, the high pressure in the blood 
vessels would force more fluids out into the tissues. It also 
acts as a plasma carrier by non specifically binding several 
hydrophobic steroid hormones and a transport protein for 
hemin and fatty acids. Too much or too little circulating 
serum albumin may be harmful. 
Serum albumin is important blood volume by maintaining 
the oncotic pressure of the blood compartment. They also 
serve as carriers for molecules of low water solubility this 
way isolating their hydrophobic nature, including lipid 
soluble hormones, bile salts, unconjugated bilirubin , free 
fatty acids calcium , ions and some drugs like warfarin, 
phenobutazone, clofibrate and phenytoin .For this reason it 
is sometimes referred as a molecular taxi . Competition 
between drugs for albumin binding sites may cause drug 
interaction by increasing the free fraction of one of the 
drugs, thereby affecting potency. 
Normal range of albumin in adults is 3.5 to 5 g/dl. If you 
have a lower albumin level, you may have malnutrition. It 
can also mean that you have liver disease or an 
inflammatory disease. Higher albumin levels may be caused 
by acute infections, burns, and stress from surgery or a heart 
attack. [8] 
Functions:  
Albumin functions primarily as a carrier protein for steroids, 
fatty acids, and thyroid hormones in the blood and plays a 
major role in stabilizing extracellular fluid volume by 
contributing to oncotic pressure ( known also as colloid 
osmotic pressure ) of plasma. 
Synthesis: 
Albumin is synthesized in the liver as pre proalbumin which 
has an N-terminal peptide that is removed before the 
nascent protein is released from the rough endoplasmic 
reticulum. The product ,proalbumin , is in turn cleaved in the 
Golgi vesicles to produce the secreted     albumin. [8] 
Child pugh scoring: 
Child Pugh scoring is based on the values of lab parameters 
which include – total bilirubin in blood (mg/dl), serum 
albumin (mg/dl), Prothrombin and INR, Ascites, and stage of 
Hepatic encephalopathy. Child pugh score is used to grade 
the extent of liver damage. 
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Table-1: Child-Pugh Scoring. 
Factor  1 point 2 points 3 points 
Total bilirubin (mg/dl) <34   34-50 >50 
Serum albumin (g/L) >3.5 28-35 <28 
PT and INR <1.7 1.71-2.30 >2.30 
Ascites None Mild Moderate to Severe 
Hepatic encephalopathy None Grade I-II (or suppressed with 
medication) 
Grade III-IV (or refractory) 
 
Grades of child pugh score: 
Table-2 Grades of liver cirrhosis with child pugh score. 
Child-Pugh 
grade 
Child-Pugh 
Score 
Indicates 
A 5-6  Well-functioning 
liver 
B 7-9  Significant 
functional 
compromise 
C 10-15  De-compensation 
of the liver 
 
Laboratory Investigations: 
The following lab investigations are usually performed to 
estimate the functionality of liver. Table-3. 
Prothrombin Time: 
Prothrombin is a protein made by the liver. Prothrombin 
helps blood to make normal clots. The "prothrombin time" 
(PT) is one way of measuring how long it takes blood to form 
a clot, and it is measured in seconds (such as 13.2 seconds). A 
normal PT indicates that a normal amount of blood-clotting 
protein is available. 
When the PT is high, it takes longer for the blood to clot (17 
seconds, for example). This usually happens because the 
liver is not making the right amount of blood clotting 
proteins, so the clotting process takes longer. A high PT 
usually means that there is serious liver damage or 
cirrhosis.Some patients take a drug called Coumadin 
(warfarin), which elevates the PT for the purpose of 
"thinning" the blood. This is not related to having liver 
disease because it is the Coumadin causing the PT to be high 
 
Table-3 Lab Investigations usually performed to estimate liver functionality. 
Laboratory test Normal range Disease  
Specific 
values 
Bilirubin 0.3-1.2 mg/dl >2 mg/dl 
Aspartate aminotransferase(AST) SGOT 5-40 U/L 120U/L 
Alanine aminotransferase 
(ALT) 
SGPT 
7-56 U/L >40 U/L 
Prothrombine 
time (PT) 
9.5-13 secs > 13.5 secs 
INR 1.0 or below Greater than 1 
Albumin 3.5-5.2 g/dl <3 g/dl 
 
INR (international normalized ratio): 
International normalized ratio (INR) is blood-clotting test. It 
is a test used to measure how quickly your blood forms a 
clot, compared with normal clotting time.  
A normal INR is 1.0. Each increase of 0.1 means the blood is 
slightly thinner (it takes longer to clot). INR is related to the 
prothrombin time (PT). If there is serious liver disease and 
cirrhosis, the liver may not produce the normal amount of 
proteins and then the blood is not able to clot normally. 
When your doctor is evaluating the function of your liver, a 
high INR usually means that the liver is not working as well 
as it could because it is not making the blood clot normally. 
[9]  
Liver disease is the most likely diagnosis if the AST level is 
more than twice that of ALT , a ratio some studies have 
found in more than 80 percent of alcoholic liver disease 
patients. An elevated level of the liver enzyme GGT is 
another gauge of heavy alcohol use and liver injury.[10] 
 
Treatment: 
Conventionally, either Ursodeoxycholic acid or S-Adenosyl 
Methionine are being used as medical interventions in 
Alcoholic Liver Disease. 
Ursodeoxycholic acid: 
Ursodiol, a naturally occurring hydrophilic bile acid, derived 
from cholesterol, is present as a minor fraction of the total 
human bile acid pool.  Oral administration of ursodiol 
increases this fraction in a dose related manner, to become 
the major biliary acid, replacing/displacing toxic 
concentrations of endogenous hydrophobic bile acids that 
tend to accumulate in cholestatic liver disease. In addition to 
the replacement and displacement of toxic bile acids, other 
mechanisms of action include cytoprotection of the injured 
bile duct epithelial cells (cholangiocytes) against toxic effects 
of bile acids, inhibition of apotosis of  hepatocytes, 
immunemodulatory effects, and stimulation of bile secretion 
by hepatocytes and cholangiocytes. [11] 
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S-Adenosyl Methionine: 
S-Adenosylmethionine (SAMe) is a natural substance present 
in the cells of the body. It is a direct metabolite of the 
essential amino acid L-methionine. SAMe plays a crucial 
biochemical role in the body by donating a one-carbon 
methyl group in a process called transmethylation. SAMe, 
formed from the reaction of L-methionine and adenosine 
triphosphate catalyzed by the enzyme S-adenosylmethionine 
synthetase, is the methyl-group donor in the biosynthesis of 
both DNA and RNA nucleic acids, phospholipids, proteins, 
epinephrine, melatonin, creatine and other molecules.[12] 
Aims and Objectives: 
Aim: 
To evaluate the outcomes of Ursodeoxycholic acid(300mg), 
methionine(200mg) and abstinence in the treatment of 
alcoholic liver disease. 
Objectives of the study: 
To compare the following Endpoints: 
Primary Endpoint-change from baseline in particular LFT 
parameter-albumin and CBP parameters such as PT and INR 
ratio. 
SECONDARY ENDPOINT- effects of Ursodeoxycholic acid and 
methionine on other LFT parameters such as total bilirubin, 
SGOT, SGPT along with changes in the above parameters in 
patients with abstinence. 
Significance: 
Alcoholic liver disease is a major cause of mortality and 
morbidity worldwide. 
Although the disease condition cannot be cured completely 
by alcohol abstinence due to very poor outcome, to improve 
patients quality of life, these drugs(ursodeoxycholic acidand 
methionine) were being used in the treatment of ALD 
patients widely.  
Though ursodeoxycholic acid and methione drugs have well 
known effect on the liver function test parameters of SGOT 
and SGPT and total bilirubin, here we assessed the effects of 
these two drugs on specific LFT parameters  i.e albumin and 
CBP parameters i.e  prothrombin and INR that may help us to 
know more about the drugs efficacy.  
Apart from the clinical management the abstinence(control 
group) was also included  to observe for the changes in the 
particular parameters(LFT and CBP) in comparison  with the 
patients treated with ursodeoxycholic acid and methionine. 
MATERIALS AND METHODS: 
Study Site: 
GANDHI HOSPITAL:It is a 1200 beded government hospital 
located at secunderabad. The Gastroenterology department 
has both out - patient and in- patient department and the 
patient flow will be around 100 to 150 patients per day.70 
cases are collected from here. 
ASIAN INSTITUTE OF GASTROENTEROLOGY: It is a 1000 
beded Super-speciality hospital located at Somajiguda 
Hyderabad. It has got both in-patient and out-patient 
department and the patient out flow will be around 40 to 50 
per day.50 cases are collected from here. 
Study design: Randomized, Observational, and prospective 
study. 
 
Study duration: 
The study is carried out over a period of 6 months, AUGUST 
2018 TO FEBRUARY 2019. 
Sample size:  Total 120 subjects. (N=120) 
GROUP -1: 40 subjects. 
GROUP - 2: 40 subjects. 
GROUP - 3: 40 subjects. 
Ethical considerations: 
The study was approved by Institutional Review Board. 
Inclusion and Exclusion criteria: 
Inclusion criteria: 
 Patients diagnosed with alcoholic liver diseasein in-
patient and out-patient department. 
 Patients above 15 years of age. 
 Male and female patients. 
 Patients diagnosed with alcohol liver disease and 
CHILD PUGH SCORE below 10 (class B- Moderately 
severe liver disease) were included. 
Exclusion criteria: 
 Patients below 15 years of age. 
 Patients who are diagnosed with grade 3 Cirrhosis. 
 Patients with CHILD PUGH SCORE above 10 (class C-
most severe liver disease) were excluded. 
Source of data: 
Review of patient records, laboratory data, direct 
communication with patients and their care takers. 
Statistical analysis:  
 Base-line Mean values of all LFT parameters, End-point 
mean values of all LFT parameters, Percentage reduction in 
mean values from Base-line to End-point. 
Parameters  considered: 
Demographics of patient. 
Laboratory parameters includes –liver function test, 
complete blood picture,  
In particular Liver function test parameters meant for the 
study are Bilirubin, SGOT, SGPT, Albumin.  
 In particular CBP parameters meant for the study are 
Prothrombin time and INR ratio. 
Study procedure: 
 Preparation of required documentation form for the 
case study of each person who were eligible for the 
study. 
 The patients who reached the inclusion criteria are 
enrolled in the study. 
 Both the in patients and out patients are reviewed on 
daily basis. 
 The study has been explained to the patient / care 
takers. 
 All the necessary information collected from patient 
record, laboratory data and documented. 
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 Their contact numbers were also been taken for the 
direct communication with patients and their care 
takers. 
 Providing the medications and explaining regarding the 
dose to be administrated.  
 Explained about the supportive care and diet for the 
patients of placebo group. 
 Review of the data based on the requirement on time 
i.e for every 1 month upto 6 months . 
 Interpretation of the data generated for seeking the 
result. 
 All the above information was collected in properly 
designed data collection form, data were analyzed 
based on requirements. 
Study Design: 
A simple randomized study to evaluate the outcomes of 
ursodeoxycholicacid,S-adenosyl methionine and placebo in 
the treatment of alcoholic liver disease. During the screening, 
subjects who are willing to give consent will be evaluated for 
all the eligibility criteria.Eligible subjects clinically diagnosed 
with alcoholic liver disease and who are above 15 years of 
age and subjects with child pugh score below 10 (class B-
moderate severe liver disease) were included in the study. 
Subjects fulfilling all the inclusion criteria and none of the 
exclusion criteria will be randomized on day 1. 
Subjects were assigned into three groups i.e, Group 1, Group 
2, Group 3. Group 1 subjects were assisted to administer 
Ursodeoxycholic acid 300 mg twice daily through oral route, 
Group were assisted to administer methionine 200mg twice 
daily through oral route and Group 3 were assisted to take 
the(abstinence) supportive care. All the three groups were 
advised to remain abstained from alcohol during the study 
period. 
Subjects were assessed with LFT parameters such as 
bilirubin, SGOT, SGPT, albumin and CBP parameters such as 
prothrombin time and INR ratio. Adverse events and 
concomitant medications were assessed from baseline to end 
of the study/visit-6. 
All the subjects were assessed for primary endpoint i.e, 
change from baseline in particular LFT parameter-albumin 
and CBP parameters such as PT and INR ratio, secondary 
endpoint i.e, effects of ursodeoxycholic acid and methionine 
on other LFT parameters such as total bilirubin, SGOT, SGPT 
along with changes in the above parameters in patients with 
abstinence. 
RESULTS AND DISCUSSION: 
The patients were included in the study from in-patient and 
out-patient department of gastroenterology. 
All the subjects who fulfilled inclusion criteria are randomly 
assigned into 3 groups i.e  Group 1(Ursodeoxycholic acid 
300mg) Group 2 (Methionine 400 mg) and Group 3 
(Abstinence) 
The randomised subjects are explained about the project and 
asked for their consent to participate in the study. 
Base line values of six parameters were noted: 
Total bilirubin. 
SGOT. 
SGPT. 
Albumin. 
Prothrombin time. 
INR ratio. 
Later, the subjects were randomised based on child pugh 
score (below10 ). The group 1 and group 2 are prescribed 
with Ursodeoxycholic acid and Methionine respectively and 
group 3 were instructed to adhere to supportive care 
(Nutritional supplements and abstinence from alcohol). All 
the 3 groups were mandated to remain abstained from 
alcohol.  
Subjects were instructed to come for a review on monthly 
basis for the assessment of the laboratory parameters upto 6 
months from the date of inclusion in the study. 
By assessing the particular parameters of the study, we 
concluded the following outcomes: 
At the end of the study, group 1 has shown 60% 
improvement. 
Group 2 has shown 50 % improvement from baseline to the 
end of the study. 
Group 3 has not shown much improvement when compared 
to the study medications i.e there is an overall improvement 
of only 30 % from baseline. 
Means of individual groups: 
Group 1:  
After assessing the overall LFT parameters  
The baseline mean of Total bilirubin was found to be 
2.9mg/dL and mean at the end of the study was found to be 
1.1 mg/dL. At the end of the study period the percentage 
reduction of mean of total bilirubin was found to be 62 %.  
The baseline mean of SGOT was found to be 98.2 U/L and 
mean at the end of study was found to be 45.4U/L and the 
percentage reduction in the mean of SGOT was noticed as 
53.7% at the end of the study. 
Baseline mean of SGPT was found to be 72.1U/L and the 
mean at the end of the study was observed as 49.1U/L. 
Percentage reduction in the mean of SGPT was found to be 
31.9% by the end of the study. 
Baseline mean of albumin was found to be 2.6 g/dL and the 
mean at the end of the study was observed as 3.7g/dL. 
Percentage increase in the mean of albumin was found to be 
42.3 % from baseline at the end of the study. 
 Baseline mean of prothrombin time was found to be 21.3s 
and the mean at the end of the study was observed as 14s.  
Percentage reduction in the mean of prothrombin time was 
found to be 34.2 % from baseline at the end of the study. 
Baseline mean of INR was found to be 1.5 and the mean at 
the end of the study was observed as 1.0. Percentage 
reduction in the mean of INR was found to be 33.3 % at the 
end of the study. 
Group 2: 
The baseline mean of Total bilirubin was found to be 
3.44mg/dl and mean at the end of the study was found to be 
1.70mg/dl. The percentage reduction in the  mean of total 
bilirubin was found to be 50 % at the end of the study.  
The baseline mean of SGOT was found to be 104.9U/L and 
mean at the end of study was found to be 57.43U/L. 
percentage reduction in the mean of SGOT was found to be  
45.2% at the end of the study. 
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Baseline mean of SGPT was found to be 60.4U/L and the 
mean at the end of the study was observed as 46.8U/L. 
Percentage reduction in the mean of SGPT was found to be 
23% at the end of the study. 
Baseline mean of albumin was found to be 1.88g/dl and the 
mean at the end of the study was observed as2.8g/dl. 
Percentage reduction in the mean of albumin was found to 
be 49% at the end of the study. 
 Baseline mean of prothrombin time was found to be 16.9s 
and the mean at the end of the study was observed as13.5s.  
Percentage reduction in the mean of prothrombin time was 
found to be 20 % at the end of the study. 
Baseline mean of INR was found to be 1.2 and the mean at 
the end of the study was observed as 0.9. Percentage 
reduction in the mean of INR was found to be 21.2 % at the 
end of the study. 
Group 3:  
The baseline mean of Total bilirubin was found to be 
1.7mg/dl and mean at the end of the study was found to be 
1.1mg/dl. percentage reduction in the mean of total bilirubin 
was found to be 37 % at the end of the study.  
The baseline mean of SGOT was found to be 93U/L and mean 
at the end of study was found to be 64U/L. percentage 
reduction in the mean of SGOT was noticed as 31 % at the 
end of the study. 
Baseline mean of SGPT was found to be 58.4U/L and the 
mean at the end of the study was observed as 40.6U/L. 
Percentage reduction in the mean of SGPT was found to be 
30 % at the end of the study. 
Baseline mean of albumin was found to be 2.1g/dl and the 
mean at the end of the study was observed as 2.7g/dl. 
Percentage increase of mean of albumin was found to be 
28.5% at the end of the study. 
 Baseline mean of prothrombin time was found to be 16.7s 
and the mean at the end of the study was observed as 14.2s.  
Percentage reduction in the mean of prothrombin time was 
found to be 14 % at the end of the study. 
Baseline mean of INR was found to be 1.2 and the mean at 
the end of the study was observed as 1.0. Percentage 
reduction of mean of INR was found to be 16 % at the end of 
the study. 
To decrease the progress of the present condition the 
complete abstinence was instructed to patients of all the 
three groups, regardless of which some patients consumed 
alcohol without any confession but it was assessed by their 
laboratory parameters. 
12% of patients in the group 1 and 8% of patients in group 2 
and 5% of patients in group 3 have respectively reported a 
maximum of 2 episodes of drinking but they were permitted 
to stay in the study without further drinking. The measured 
outcomes were affected by these episodes of drinking. 
Adverse Events: 
As these drugs comes with a positive effect and less or more 
negative effect here few patients have experienced the 
adverse reactions. 
There were no severe adverse events in either three groups. 
In Group1 (ursodeoxycholic acid), 2 patients complained of 
diarrhea, 3 patients complained of headache. In Group2 
(methionine) no serious adverse events were reported. In 
Group3 (abstinence) 3 subjects complained of vomitings, 2 
subjects complained of headache. 
CONCLUSION 
By the end of the study scruitinizing all the laboratory 
parameters it is   observed thatof the three groups group 1 
and group 2 has better treatment outcomes than group 3 and 
hence it is concluded that medical intervention is more 
effective over complete abstinence. 
As Group 1 has shown 60% of improvement, Group 2 has 
shown 50% of improvement from baseline to end of the 
study period comparatively on the other hand complete 
abstinence has shown a poor improvement of 30% from 
baseline to the end of the study periods.  
Considering all the above observed outcomes it is concluded 
that early medical intervention is a better option for better 
outcomes and among Ursodeoxycholic acid and methionine, 
Ursodeoxycholic acid was found to be better option for the 
treatment. 
ACKNOWLEDGEMENT 
We would like to express our gratitude to everyone who was 
instrumental in this study. 
Special thanks to Medical Director, Gandhi Hospital, 
Secunderabad and Management of Asian Institute Of 
Gastroenterology, Somajiguda,Hyderabad. 
ABBREVATIONS USED 
1) AIDS-Acquired Immune Deficiency Syndrome 
2) ALD-Alcoholic Liver Disease 
3) ALT-Alanine Amino Transferase 
4) AST-Aspirate Amino Transferase 
5) ATP-Adenosine Triphosphate 
6) CBP-Complete Blood Picture 
7) CNS-Central Nervous System 
8) DNA-Deoxyribo Nucleic Acid  
9) GABA-Gamma Amino Butyric Acid 
10) GGT-Gamma Glutamyl Transferase 
11) IL-Interleukin 
12) INR-International Normalized Ratio 
13) LFT-Liver Functional Test 
14) NAD-Nicotinamide Adenine Dinucleotide 
15) NADH- Nicotinamide Adenine Dinucleotide Hydrogen 
16) NCRB-National Crime Records Bureau 
17) PBC-Primary Biliary Cirrhosis 
18) PEG-Poly Ethylene Glycol 
19) PT-Prothrombin Time 
20) RNA-Ribonucleic Acid 
21) ROS-Reactive Oxygen Species 
22) SAM-S-Adenosyl Methionine 
23) SGOT-Serum Glutamic Oxaloacetic Transaminase 
24) SGPT-Serum Glutamic Pyruvic Transaminase 
25) TNF-Tumor Necrosis Factor 
26) UDCA-Ursodeoxycholic Acid 
27) WHO-World Health Organization 
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